arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Immunome Inc.

IMNM

$25.01 ▼ -0.86 (-3.32%) at close

8 Visible periods

26 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Immunome Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.2B

Dividend Yield —

Revenue Growth -23.2% ↗

Op. Margin —

ROIC -27.9% ↗

FCF / Share $-2.30 ↘

Trailing P/E —

Price / Book 4.5x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$6.94M

↓ -23.2% —

Net Income Profit after all expenses

$-212.39M

↑ +27.5% —

FCF / Share Free cash flow per share

$-2.30

↓ -14.2% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue Growth YoY (%)	-23.2% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-390%)	-35.5% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-544%)	—	—	—	—	—	—
EPS Growth YoY (%)	51.4% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	7.1% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	-74.1% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-44.4% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	59.3% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	27.5% Excellent ↑ Excellent Improving Year-over-year change in net income	-174.3% Weak ↓ Weak Declining Year-over-year change in net income	-189.5% Weak ↓ Weak Declining Year-over-year change in net income	-49.3% Weak ↑ Weak Improving Year-over-year change in net income	-38.5% Weak Weak Year-over-year change in net income	-70.8% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-14.2% Weak ↑ Weak Improving Year-over-year change in free cash flow	-375.3% Weak ↓ Weak Declining Year-over-year change in free cash flow	82.3% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-50.4% Weak Weak Year-over-year change in free cash flow	57.7% Excellent Excellent Year-over-year change in free cash flow	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
FCF Margin (%) (%)	—	—	-59.9% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—
FCF / Net Income (x)	0.94x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.40x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.08x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.78x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.74x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.71x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Return on Invested Capital (%)	-27.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-133.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-72.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-175.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-41.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-23.4% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	22.9% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-32.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-127.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-73.7% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-153.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-43.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-27.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	-204.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-33.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-323%)	-161.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1178%)	-89.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-694%)	-221.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1577%)	-51.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-442%)	-43.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-388%)	29.3% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+95%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Debt to Equity (x)	—	—	—	—	—	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-99%)	—	—
Interest Coverage (x)	—	—	—	—	-1800.29x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-422.79x Weak Weak Operating income divided by interest expense Optimal: > 5x	-224.96x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-653.48M	$-143.35M	$-98.68M	$-20.32M	$-49.23M	$-39.63M	$-2.54M	—
Debt / EBITDA (x)	—	—	—	—	—	-0.01x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue per Share (USD)	$0.08	$0.15	$0.71	—	—	—	—	—
Basic EPS, GAAP (USD)	$-2.43	$-5.00	$-5.38	$-3.09	$-2.14	$-5.26	—	—
Free Cash Flow per Share (USD)	$-2.30	$-2.01	$-0.42	$-2.39	$-1.59	$-3.75	—	—
Book Value per Share (USD)	$5.61	$2.81	$2.77	$1.37	$3.98	$3.89	$-32.41	—
Tangible Book Value per Share (USD)	$5.61	$2.81	$2.77	$1.37	$3.98	$3.89	$-32.41	—
Basic Weighted Avg Shares (shares)	87.35M	58.64M	19.84M	12.13M	11.54M	3.39M	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Working Capital (USD)	$615.79M	$167.03M	$122.87M	$15.32M	$46.91M	$39.86M	$1.46M	—
LT Debt (USD)	—	—	—	—	—	$134.00K	—	—
Total Equity (USD)	$634.34M	$181.16M	$119.88M	$16.65M	$48.19M	$41.34M	$-35.63M	$-25.20M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Sales/Revenue/Turnover (USD)	$6.94M	$9.04M	$14.02M	—	—	—	—	—
Depreciation Expense (USD)	$2.47M	$1.57M	$457.00K	$422.00K	$755.00K	$755.00K	$615.00K	—
Net Income, GAAP (USD)	$-212.39M	$-292.96M	$-106.81M	$-36.90M	$-24.71M	$-17.84M	$-10.44M	—
Operating Cash Flow (USD)	$-190.92M	$-110.79M	$-7.57M	$-28.69M	$-18.23M	$-12.13M	$-9.60M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 29 quarters

Immunome Inc.

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare IMNM with peers